Status:

COMPLETED

Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer

Lead Sponsor:

University of Birmingham

Collaborating Sponsors:

Childhood Liver Tumours Strategy Group - SIOPEL

Conditions:

Liver Cancer

Ototoxicity

Eligibility:

All Genders

1-18 years

Phase:

PHASE3

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs...

Detailed Description

OBJECTIVES: Primary * To assess the efficacy of sodium thiosulfate (STS) to reduce the hearing impairment caused by cisplatin chemotherapy. Secondary * To carefully monitor any potential impact of...

Eligibility Criteria

Inclusion

  • Inclusion Histologically confirmed newly diagnosed hepatoblastoma
  • Standard risk hepatoblastoma (Pretext I,II,III)
  • Age ≤ 18 years and \> 1 month
  • Written informed consent and national/local ethics committee and regulatory approval
  • Centre/country willing and able to organise audiometry at the minimum required quality standard and to provide the contact details of the Consultant Audiologist or Ear Nose and Throat Surgeon who will take the responsibility for seeing that this is done
  • Ability to comply with requirements for submission of material for central review
  • For females of child-bearing potential, a negative pregnancy test prior to study treatment is required.
  • Any patient who is of reproductive age should agree to use adequate contraception for the duration of the trial.
  • Exclusion:
  • High risk hepatoblastoma
  • Hepatocellular carcinoma
  • Treatment starting more than 15 days from written biopsy report
  • Abnormal renal function
  • Any previous chemotherapy
  • Recurrent disease
  • Previous hypersensitivity to STS
  • Patient unable to follow the protocol for any reason

Exclusion

    Key Trial Info

    Start Date :

    December 15 2007

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    February 28 2018

    Estimated Enrollment :

    116 Patients enrolled

    Trial Details

    Trial ID

    NCT00652132

    Start Date

    December 15 2007

    End Date

    February 28 2018

    Last Update

    May 29 2018

    Active Locations (16)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 4 (16 locations)

    1

    Birmingham Children's Hospital

    Birmingham, England, United Kingdom, B4 6NH

    2

    Bristol Royal Hospital for Childre

    Bristol, England, United Kingdom, BS2 8AE

    3

    Addenbrooke's Hospital

    Cambridge, England, United Kingdom, CB2 2QQ

    4

    Royal Marsden - London

    London, England, United Kingdom, SW3 6JJ